Back HIV Treatment

HIV Treatment

HIV R4P: Positive Response to "Gift Tokens for Undetectable Viral Load" Trial

A U.S. study presented at last month’s HIV Research for Prevention conference found generally positive responses among people with HIV and clinic staff to a trial that used $70 gift tokens as an incentive for people to attend clinic visits regularly, refill their HIV treatment prescriptions, and maintain an undetectable viral load. However, the study found that only just under half of patients had an accurate understanding of what viral load was, and that this did not improve during the study.

alt

Read more:

Delaying Treatment More than 12 Months after HIV Infection Reduces CD4 Cell Recovery

People with HIV who start antiretroviral therapy (ART) more than a year after seroconversion have a lower likelihood of regaining normal CD4 T-cell counts, researchers reported in the November 24 online edition of JAMA Internal Medicine. "If full restoration of immunologic and clinical health is our goal, then the present study tells us that the best chance we have is to start antiretroviral therapy within 12 months of infection," according to an accompanying editorial.

alt

Read more:

HIV Drug Therapy: Once-daily Dolutegravir Superior to Darunavir at 96 Weeks

Treatment with a triple antiretroviral combination containing the once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported this month at the HIV Drug Therapy Glasgow conference.

alt

Read more:

Complete Coverage of HIV Drug Therapy 2014

HIVandHepatitis.com coverage of the HIV Drug Therapy 2014 Conference Research, November 2-6, 2014, in Glasgow, Scotland.

Full listing of coverage by topic

HIV Drug Therapy 2014 website

11/4/14

alt

HIV Drug Therapy: Darunavir/Ritonavir Protease Inhibitor Monotherapy Less Effective than 3-Drug ART

Monotherapy with ritonavir-boosted darunavir (Prezista) results in a lower rate of viral suppression after 48 weeks when compared to darunavir/ritonavir plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), but may be just as effective as 3-drug therapy in people with nadir (lowest-ever) CD4 cell counts above 200 cells/mm3, according to a 48-week analysis of the PROTEA study presented last week at the HIV Drug Therapy Glasgow conference.

alt

Read more: